Status: Recruiting
Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.
Participants needed: 436
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Tourcoing HospitalUpdated: May 10, 2022Locations: 30
Eligibility criteria
Hip or knee Prosthetic joint infection treated by debridement, antibiotic therap... [+8]
Suspicion of reduce absorption of oral treatment due to abdominal disorder Known... [+16]